The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

A new Yale study has found a promising target for treating the brain fog that can follow COVID-19 and offers new insight into ...

Depressive symptoms were not consistently associated with Alzheimer's pathology in people without dementia. In people with normal cognition, amyloid and depressive symptoms were not linked. In ...

Signs of Alzheimer’s disease could be detectable in the blood as early as middle age, a study has found, raising hopes that ...

An increased amyloid-β load is not a benign result of aging; it is associated with lower cognitive performance and poor ...

The US Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for ...

New research shows that signs of Alzheimer’s disease can already be detected in the blood of people as young as their 40s.

Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...

A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...